Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth

References

• Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, et al. GLIPR1-DeltaTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer 2015; 14:122; PMID:26084402; https://doi.org/10.1186/s12943-015-0395-0
   PubMed Web of Science ®Google Scholar
• Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: Mechanisms, targets, and treatment. Prostate Cancer 2012; 2012:327253; PMID:22530130; https://doi.org/10.1155/2012/327253
   PubMedGoogle Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-48; PMID:23228172; https://doi.org/10.1056/NEJMoa1209096
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; https://doi.org/10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One 2013; 8:e63563; PMID:23704919; https://doi.org/10.1371/journal.pone.0063563
   PubMed Web of Science ®Google Scholar
• Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PloS One 2011; 6:e27970; PMID:22114732; https://doi.org/10.1371/journal.pone.0027970
   PubMed Web of Science ®Google Scholar
• Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci 2014; 10:627-42; PMID:24948876; https://doi.org/10.7150/ijbs.8756
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8:976-90; PMID:19029958; https://doi.org/10.1038/nrc2231
   PubMed Web of Science ®Google Scholar
• Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012; 18:5546-53; PMID:23071356; https://doi.org/10.1158/1078-0432.CCR-12-0977
   PubMed Web of Science ®Google Scholar
• Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152-60; PMID:18329957; https://doi.org/10.1016/j.molmed.2008.02.001
   PubMed Web of Science ®Google Scholar
• Sears RC. The life cycle of C-Myc: From synthesis to degradation. Cell Cycle 2004; 3:1133-7; PMID:15467447; https://doi.org/10.4161/cc.3.9.1145
   PubMed Web of Science ®Google Scholar
• Tibbitts DC, Escamilla-Powers JR, Zhang X, Sears RC. Studying c-Myc serine 62 phosphorylation in leukemia cells: Concern over antibody cross-reactivity. Blood 2012; 119:5334-5; PMID:22653959; https://doi.org/10.1182/blood-2012-03-414532
   PubMed Web of Science ®Google Scholar
• Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14:2501-14; PMID:11018017; https://doi.org/10.1101/gad.836800
   PubMed Web of Science ®Google Scholar
• Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112:1724-31; PMID:14660748; https://doi.org/10.1172/JCI200319035
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med 2013; 368:1458-9; PMID:23574133; https://doi.org/10.1056/NEJMoa1209096
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther 2013; 14:962-72; PMID:24025258; https://doi.org/10.4161/cbt.25943
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther 2015; 14:1884-95; PMID:26056150; https://doi.org/10.1158/1535-7163.MCT-14-1057
   PubMed Web of Science ®Google Scholar
• Sivertsen A, Torfoss V, Isaksson J, Ausbacher D, Anderssen T, Brandsdal BO, Havelkova M, Skjorholm AE, Strom MB. Anticancer potency of small linear and cyclic tetrapeptides and pharmacokinetic investigations of peptide binding to human serum albumin. J Peptide Sci 2014; 20:279-91; PMID:24677781; https://doi.org/10.1002/psc.2615
   PubMed Web of Science ®Google Scholar
• Murray BC, Peterson MT, Fecik RA. Chemistry and biology of tubulysins: Antimitotic tetrapeptides with activity against drug resistant cancers. Nat Prod Rep 2015; 32:654-62; PMID:25677951; https://doi.org/10.1039/C4NP00036F
   PubMed Web of Science ®Google Scholar
• Neviani P, Perrotti D. SETting OP449 into the PP2A-activating drug family. Clin Cancer Res 2014; 20:2026-8; PMID:24634375; https://doi.org/10.1158/1078-0432.CCR-14-0166
   PubMed Web of Science ®Google Scholar
• Saito T, Hirai H, Kim YJ, Kojima Y, Matsunaga Y, Nishida H, Sakakibara T, Suga O, Sujaku T, Kojima N. CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502. J Antibiot (Tokyo) 2002; 55:847-54; PMID:12523817; https://doi.org/10.7164/antibiotics.55.847
   PubMed Web of Science ®Google Scholar
• Ross NC, Kulkarni SS, McLaughlin JP, Aldrich JV. Synthesis of CJ-15,208, a novel kappa-opioid receptor antagonist. Tetrahedron Lett 2010; 51:5020-3; PMID:22865937; https://doi.org/10.1016/j.tetlet.2010.07.086
   PubMed Web of Science ®Google Scholar
• Ross NC, Reilley KJ, Murray TF, Aldrich JV, McLaughlin JP. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting kappa opioid receptor antagonism. Br J Pharmacol 2012; 165:1097-108; PMID:21671905; https://doi.org/10.1111/j.1476-5381.2011.01544.x
   PubMed Web of Science ®Google Scholar
• Aldrich JV, Senadheera SN, Ross NC, Ganno ML, Eans SO, McLaughlin JP. The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J Nat Prod 2013; 76:433-8; PMID:23327691; https://doi.org/10.1021/np300697k
   PubMed Web of Science ®Google Scholar
• Eans SO, Ganno ML, Reilley KJ, Patkar KA, Senadheera SN, Aldrich JV, McLaughlin JP. The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting kappa opioid receptor antagonism in the CNS after oral administration. Br J Pharmacol 2013; 169:426-36; PMID:23425081; https://doi.org/10.1111/bph.12132
   PubMed Web of Science ®Google Scholar
• Fichna J, Janecka A. Opioid peptides in cancer. Cancer Metastasis Rev 2004; 23:351-66; PMID:15197335; https://doi.org/10.1023/B:CANC.0000031773.46458.63
   PubMed Web of Science ®Google Scholar
• Gach K, Wyrebska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 2011; 384:221-30; PMID:21800094; https://doi.org/10.1007/s00210-011-0672-4
   PubMed Web of Science ®Google Scholar
• Moon TD. The effect of opiates upon prostatic carcinoma cell growth. Biochem Biophys Res Commun 1988; 153:722-7; PMID:2898243; https://doi.org/10.1016/S0006-291X(88)81154-9
   PubMed Web of Science ®Google Scholar
• Kuzumaki N, Suzuki A, Narita M, Hosoya T, Nagasawa A, Imai S, Yamamizu K, Morita H, Nagase H, Okada Y, et al. Effect of kappa-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. Br J Cancer 2012; 106:1148-52; PMID:22343623; https://doi.org/10.1038/bjc.2011.574
   PubMed Web of Science ®Google Scholar
• Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004; 6:308-18; PMID:15048125; https://doi.org/10.1038/ncb1110
   PubMed Web of Science ®Google Scholar
• Patkar KA, Yan X, Murray TF, Aldrich JV. [Nα-benzylTyr1,cyclo(D-Asp5,Dap8)]-dynorphin A-(1-11)NH2 cyclized in the “address” domain is a novel kappa-opioid receptor antagonist. J Med Chem 2005; 48:4500-3; PMID:15999987; https://doi.org/10.1021/jm050105i
   PubMed Web of Science ®Google Scholar
• Arttamangkul S, Ishmael JE, Murray TF, Grandy DK, DeLander GE, Kieffer BL, Aldrich JV. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the “address” sequence. J Med Chem 1997; 40:1211-8; PMID:9111295; https://doi.org/10.1021/jm960753p
   PubMed Web of Science ®Google Scholar
• Pelengaris S, Khan M, Evan G. c-MYC: More than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76; PMID:12360279; https://doi.org/10.1038/nrc904
   PubMed Web of Science ®Google Scholar
• Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013; 122:1923-34; PMID:23926298; https://doi.org/10.1182/blood-2013-03-492181
   PubMed Web of Science ®Google Scholar
• Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992; 257:1261-4; PMID:1325671; https://doi.org/10.1126/science.1325671
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8:355-68; PMID:16286244; https://doi.org/10.1016/j.ccr.2005.10.015
   PubMed Web of Science ®Google Scholar
• Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010; 80:22-30; PMID:20206143; https://doi.org/10.1016/j.bcp.2010.02.016
   PubMed Web of Science ®Google Scholar
• Zhang JY, Tao LY, Liang YJ, Yan YY, Dai CL, Xia XK, She ZG, Lin YC, Fu LW. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G1 with involvement of GSK-3β/β-catenin/c-Myc pathway. Cell Cycle 2009; 8:2444-50; PMID:19571678; https://doi.org/10.4161/cc.8.15.9170
   PubMed Web of Science ®Google Scholar
• Thamilselvan V, Menon M, Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3β/β-catenin pathway. Int J Cancer 2011; 129:2916-27; PMID:21472727; https://doi.org/10.1002/ijc.25949
   PubMed Web of Science ®Google Scholar
• Huang HL, Weng HY, Wang LQ, Yu CH, Huang QJ, Zhao PP, Wen JZ, Zhou H, Qu LH. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther 2012; 11:1155-65; PMID:22389469; https://doi.org/10.1158/1535-7163.MCT-12-0066
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo Z, Xu L. Tributyltin induces a G2/M cell cycle arrest in human amniotic cells via PP2A inhibition-mediated inactivation of the ERK1/2 cascades. Environ Toxicol Pharmacol 2014; 37:812-8; PMID:24632106; https://doi.org/10.1016/j.etap.2014.02.009
   PubMed Web of Science ®Google Scholar
• Song A, Ye J, Zhang K, Sun L, Zhao Y, Yu H. Lentiviral vector-mediated siRNA knockdown of c-MYC: Cell growth inhibition and cell cycle arrest at G2/M phase in Jijoye cells. Biochem Genet 2013; 51:603-17; PMID:23657834; https://doi.org/10.1007/s10528-013-9590-0
   PubMed Web of Science ®Google Scholar
• Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget 2015; 6:6684-707; PMID:25788262; https://doi.org/10.18632/oncotarget.3246
   PubMed Web of Science ®Google Scholar
• Jingushi K, Nakamura T, Takahashi-Yanaga F, Matsuzaki E, Watanabe Y, Yoshihara T, Morimoto S, Sasaguri T. Differentiation-inducing factor-1 suppresses the expression of c-Myc in the human cancer cell lines. J Pharmacol Sci 2013; 121:103-9; PMID:23357875; https://doi.org/10.1254/jphs.12204FP
   PubMed Web of Science ®Google Scholar
• Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol Ther 2011; 11:1046-58; PMID:21525782; https://doi.org/10.4161/cbt.11.12.15709
   PubMed Web of Science ®Google Scholar
• Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE. In vitro model systems to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer 2013; 20:R49-64; PMID:23447570; https://doi.org/10.1530/ERC-12-0401
   PubMed Web of Science ®Google Scholar